⟵ Back to Search Results

AdvanTIG-205

Recruiting

Ociperlimab With Tislelizumab and Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer

Beigene Study ID info

AdvanTIG-205

ClinicalTrials.gov ID info

NCT05014815

EudraCT Number info

2021-001075-17

Study Overview

Sex: All

Age: 18 Years and older (Adult, Older Adult)

Accepts Healthy Volunteers? yes

No Study Documents

Locations

Study Overview

Sex: All

Age: 18 Years and older (Adult, Older Adult)

Accepts Healthy Volunteers? yes

No Study Documents